Compare AFLAC Incorporated (AFL) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs Gilead Sciences, Inc. — how do they compare? AFLAC Incorporated trades at $120.84 (market cap $60.70B), while Gilead Sciences, Inc. trades at $135 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 2.8× AFLAC Incorporated's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| AFL | GILD | |
|---|---|---|
Market Cap | $60.70B | $168.35B |
Sector | Financials | Health |
52-Week High | $129.55 | $155.80 |
52-Week Low | $103.55 | $110.56 |
Enterprise Value | $70.65B | $191.42B |
Dividend Yield | 2.02% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFL trades at $121.94, down 2.14% with bearish technical signals and recent earnings misses. The stock shows strong profitability with 26.59% net margin and 16.91% ROE, but faces revenue declines from $19.1B in 2024 to $17.4B in 2025. Recent news highlights AFL's rebranding efforts and dividend consistency amid healthcare cost pressures. Technical indicators show oversold RSI at 17.69 with support at $117.
Outlook remains cautious with mixed analyst sentiment (28% buy, 56% hold) and $118 consensus target below current price. Risks include Japan market exposure and currency headwinds, balanced by 43-year dividend growth history and strong cash flow generation. The stock offers value at 13x P/E but requires monitoring of revenue stabilization.
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
